Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 17/20 | 0.61 |
| ▸ | RARA | P10276 | 5/20 | 0.57 |
| ▸ | RARB | P10826 | 5/20 | 0.57 |
| ▸ | RARG | P13631 | 5/20 | 0.57 |
| ▸ | RXRB | P28702 | 4/20 | 0.57 |
| ▸ | RXRG | P48443 | 4/20 | 0.57 |
| ▸ | HNF4A | P41235 | 2/20 | 0.43 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.42 |
| ▸ | CYP26A1 | O43174 | 2/20 | 0.41 |
| ▸ | CYP26B1 | Q9NR63 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.41 |
| ▸ | ESR1 | P03372 | 1/20 | 0.41 |
| ▸ | PGR | P06401 | 1/20 | 0.41 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | DRD1 | P21728 | 1/20 | 0.41 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29395963 | 1.00 | RXRA (0.61) | RXRARARARARBRARGRXRB | |
| Acetic Acid SCHEMBL5879410 | 0.97 | RXRA (0.62) | RXRARARARARBRARGRXRB | |
| SCHEMBL2897683 | 0.88 | RXRA (0.64) | RXRARARARARBRARGRXRB | |
| SCHEMBL7217889 | 0.87 | RXRA (0.72) | RXRARARARARBRARGRXRB | |
| SCHEMBL6910130 | 0.85 | RXRA (0.62) | RXRARARARARBRARGRXRB | |
| SCHEMBL12418596 | 0.85 | RXRA (0.50) | RXRARARARARBRARGRXRB | |
| SCHEMBL7950320 | 0.81 | RXRA (0.57) | RXRARARARARBRARGRXRB | |
| SCHEMBL6668058 | 0.80 | RXRA (0.50) | RXRARARARARBRARGRXRB | |
| SCHEMBL8853596 | 0.80 | RXRA (0.43) | RXRARARARARBRARGRXRB | |
| SCHEMBL7946771 | 0.80 | RXRA (0.52) | RXRARARARARBRARGRXRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 238 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190276469-A1 | Cyclic Ketals As Fragrance Precursor Compounds | HENKEL AG & CO. KGAA (DE) | 2019-09-12 | — | — | US | claimed |
| US-20190010427-A1 | SILICONE COMPOUNDS | THE PROCTER & GAMBLE COMPANY | 2019-01-10 | — | — | US | claimed |
| US-20190010293-A1 | SILICONE COMPOUNDS | THE PROCTER & GAMBLE COMPANY | 2019-01-10 | — | — | US | claimed |
| CN-107151382-A | The preparation method of fragrant plastic master batch | 武汉纺织大学 | 2017-09-12 | — | — | CN | claimed |
| CN-102150625-A | Functional straw mattress | GUANGZHOU ACT IND CO LTD | 2011-08-17 | — | — | CN | claimed |
| US-20070166341-A1 | Solid volatile composition and method and system for making the same | INTERNATIONAL ARTS & SCIENCE GROUP, INC. | 2007-07-19 | — | — | US | claimed |
| US-6939845-B2 | Fragrance precursors | GIVAUDAN SA (CH) | 2005-09-06 | — | — | US | claimed |
| EP-1167362-B1 | Fragance precursors | GIVAUDAN SA (CH) | 2005-05-25 | — | — | EP | claimed |
| US-20020035055-A1 | Fragrance precursors | GIVAUDAN SA (CH) | 2002-03-21 | — | — | US | claimed |
| EP-1167362-A1 | Fragance precursors | Givaudan SA (CH) | 2002-01-02 | — | — | EP | claimed |
| EP-1146033-A2 | Fragrance precursors | Givaudan SA (CH) | 2001-10-17 | — | — | EP | claimed |
| US-5554588-A | IN WHICH AT LEAST HALF COMPRISES ETHERS, AROMATIC METHYL KETONES, ALCOHOLS, ESTERS AND SALICYLATES; DEODORANTS AND ACCEPTABLE FRAGRANCE | LEVER BROTHERS COMPANY, DIVISION OF CONOPCO, INC. (US) | 1996-09-10 | — | — | US | claimed |
| US-5501805-A | CONTAINING MUSK, SALICYLATE, ADDITIONAL FRAGRANCES; HAVING LOW ODOR INTENSITY | LEVER BROTHERS COMPANY, DIVISION OF CONOPCO, INC. (US) | 1996-03-26 | — | — | US | claimed |
| EP-3881048-B1 | DEVICE FOR REMOVING VOLATILE ORGANIC COMPOUNDS | LETAT FRANCAIS REPRESENTE PAR LE MINI DE LINTERIEUR (FR) | 2026-05-06 | — | — | EP | disclosed |
| US-11820961-B2 | Musk compositions and methods of use thereof | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2023-11-21 | — | — | US | disclosed |
| EP-3313361-B1 | MUSK COMPOSITION AND METHODS OF USE THEREOF | TAKASAGO PERFUMERY CO LTD (JP) | 2023-09-13 | — | — | EP | disclosed |
| EP-0002510-A1 | Cyclohexanes, method for their preparation, their use and compositions containing them | L. Givaudan & Cie Société Anonyme (CH) | 1979-06-27 | — | — | EP | disclosed |
| US-4150019-A | COLORFAST, HEAT RESISTANT, MIGRATION | HOECHST AKTIENGESELLSCHAFT (DE) | 1979-04-17 | — | — | US | disclosed |
| US-4052341-A | 3-METHYL-5-(2,2,3-TRIMETHYLCYCLOPENT-3-EN-1-YL)PENTAN-2-OL COMPOUND AND PERFUME COMPOSITIONS | GIVAUDAN CORPORATION (US) | 1977-10-04 | — | — | US | disclosed |
| US-4018719-A | Synthetic musk perfume compound 1,1,2,3,3,5-hexamethylindan-6-nitrile | POLAK'S FRUTAL WORKS, INC. (US) | 1977-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190276469-A1 | Cyclic Ketals As Fragrance Precursor Compounds | KCNK5, KLK5, KCNA1 | RXRA 3946/4885RARA 2625/4885RARB 3978/4885 |
| US-11820961-B2 | Musk compositions and methods of use thereof | MUSK, MSI2, SYMPK | RXRA 1403/4885RARA 1615/4885RARB 1752/4885 |
| US-20020035055-A1 | Fragrance precursors | FAAH2, FDPS, CYP51A1 | RXRA 1950/4885RARA 1261/4885RARB 1482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.